New drug aims to stop nosebleeds in rare blood vessel disorder
Disease control
Not yet recruiting
This study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…
Phase: PHASE1, PHASE2 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC